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Transient receptor potential vanilloid 3 (TRPV3) was cloned from keratinocytes and 
described as a thermosensitive member of the transient receptor potential (TRP) ion channel 
family. Although its role in thermosensation is currently under debate, it is highly expressed in 
the epidermis and functions as a nonselective, Ca2+-permeable cation channel (Huang et al. 2011; 
Nilius and Bíró 2013; Peier et al. 2002). Despite its high abundance in the skin, its genetic 
deletion only causes moderate, often strain- or gender-dependent cutaneous phenotypic 
modifications, such as formation of curly whiskers and wavy hair, defect in epidermal barrier 
functions and alterations in epidermal nitrate homeostasis (Cheng et al. 2010; Miyamoto et al. 
2011). In contrast, gain-of-function mutations of TRPV3 result in dramatic cutaneous alterations 
associated with severely dry skin, dermatitis and hairless phenotype in both mice and rats 
(Asakawa et al. 2006; Xiao et al. 2008). Moreover, similar gain-of-function mutations of TRPV3 
were found to play an etiological role in a rare human genodermatosis, Olmsted syndrome, 
characterized by periorofacial hyperkeratosis, hypotrichosis, alopecia and severe pruritus (He et 
al. 2015; Lin et al. 2012; Ni et al. 2016). Encouraged by these findings, we verified the role of 
TRPV3 in human hair growth control by inducing catagen in mechanistic studies (Borbíró et al. 
2011) and, most recently, we also described the pro-inflammatory action of TRPV3 activation in 
human epidermal keratinocytes (Szöllősi et al. 2018), whereas others reported its role in dry 
skin-associated itching (Yoshioka et al. 2009). However, the extended inflammatory symptoms 
and the disrupted lipid barrier found both in rodents and human suggested that TRPV3-
expressing skin cells other than keratinocytes might also be involved in the development of 
inflammatory skin conditions induced by TRPV3 hyperfunction. Therefore, in the current study, 
we investigated the expression and activation of TRPV3 in human sebocytes, which are 
important regulators of cutaneous homeostasis (Tóth et al. 2011).  
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Immunohistochemical analysis revealed that, like epidermal keratinocytes, human 
sebaceous glands (SG) express TRPV3 in situ (Figure 1a). Peripheral undifferentiated cells show 
stronger immunopositivity than centrally located terminally differentiated cells. We also 
demonstrated the presence of TRPV3 protein and mRNA transcripts in human SG-derived SZ95 
sebocytes (Zouboulis et al. 1999), a widely accepted model cell line to study SG biology in vitro 
(Figure 1b-d). We observed that TRPV3 expression is decreased in post-confluent, more 
differentiated cultures compared to the highly proliferating preconfluent cultures (Figure 1c-d). 
Importantly, the synthetic TRPV3 activator 2-aminoethoxydiphenyl-borate (2-APB), as well as 
the plant-derived carvacrol evoked marked elevation of the intracellular Ca2+ concentration 
(Figure 1e) suggesting that TRPV3 is, indeed, functionally expressed in human sebocytes. The 
evoked Ca2+ signals were practically abolished in the presence of the general TRP channel 
blocker ruthenium red, but were not affected by either AMG9810 or HC067047, selective 
antagonists of the closely related channels TRPV1 and TRPV4, respectively (Figure 1f), which 
channels are also functionally expressed by sebocytes (Oláh et al. 2014; Tóth et al. 2009). Since 
highly specific TRPV3 activators and inhibitors are not available commercially, we then 
investigated the effect of RNAi-based silencing of TRPV3 expression on Ca2+ signals. 
Transfection of the sebocytes with siRNA targeting TRPV3 resulted in a partial, yet marked 
decrease of the channel expression (Figure S1) compared to the scrambled RNA-transfected 
cells, and significantly suppressed the amplitude and the rate of rise of the agonists evoked Ca2+ 
signals (Figure 1g-h); these data provided strong evidence for the activation of TRPV3 by the 
applied compounds. Higher concentrations of the activators reduced the living cell number in 24 
hours, but lower concentrations (still able to evoke Ca2+ signals) did not influence the viability of 
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sebocytes (Figure S2), confirming previous results on Ca2+ signaling-induced sebocyte apoptosis 
(Zouboulis et al. 2017).  
Since sebaceous lipids essentially contribute to the epidermal barrier functions, we also 
investigated the influence of TRPV3 on lipid synthesis in SZ95 cells. Activation of TRPV3 with 
non-cytotoxic concentrations of 2-APB and carvacrol decreased lipid synthesis during 
arachidonic acid (AA)-induced differentiation of scrambled RNA-transfected cells used as 
control. Importantly, TRPV3 agonists were less effective to suppress AA induced lipid synthesis 
in cells transfected with siRNA targeting TRPV3 (Figure 2a). Moreover, AA was slightly, but 
significantly more effective in TRPV3-silenced cells suggesting that basal activity of TRPV3 
also negatively regulates AA-induced lipid synthesis. Notably, the effect of TRPV3 agonists was 
not restricted to AA-induced lipid synthesis: they also inhibited the lipogenic effect of the 
endocannabinoid anandamide, and of the combination of linoleic acid and testosterone, as well 
as they slightly decreased basal lipid synthesis of non-transfected sebocytes (Figure S3). 
Moreover, carvacrol did not induce cellular differentiation as it affected cellular granulation 
neither under control conditions nor in AA-treated cells. However, carvacrol selectively inhibited 
the AA induced accumulation of cellular lipids which effect was prevented by ruthenium red 
indicating that indeed TRPV3 mediates the effect (Figure S4a). Simultaneously, carvacrol 
downregulated peroxisome proliferator-activated receptor γ (PPARγ) and nuclear receptor 
interacting protein 1 (NRIP1), important positive regulators of sebaceous lipid synthesis (Dozsa 
et al. 2014; Oláh et al. 2014). These results suggested that TRPV3 mediated Ca2+ signaling 
generally inhibits lipid synthesis of sebocytes, independently of the activated lipogenic 
pathways, confirming a current study of our group on the role of Ca2+ signaling in human 
sebocytes using another experimental setting (Zouboulis et al. 2017). Our data are consistent 
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with our previous findings as TRPV1 and TRPV4 activation by capsaicin and cannabidiol, 
respectively, inhibited sebaceous lipid synthesis (Oláh et al. 2014; Tóth et al. 2009).  
Beyond lipid synthesis, SGs play an important role in the regulation of cutaneous immune 
functions (Tóth et al. 2011). Therefore, we also assessed the effect of TRPV3 activation on 
cytokine expression of SZ95 sebocytes. Our findings revealed that transcription of several pro-
inflammatory cytokines was unambiguously triggered by the TRPV3 agonist carvacrol within 6 
hours (Figure 2b) although during this time, 2-APB was ineffective. To assess the TRPV3 
specificity of the carvacrol treatment, we repeated the experiments on TRPV3-silenced SZ95 
sebocytes. In this condition, we found a reduced effect of the activator compared to scrambled 
RNA-transfected cells (Figure 2c), again arguing for the involvement of TRPV3 in mediating the 
effect of carvacrol. Moreover, we found that not only the expression, but the release of some pro-
inflammatory cytokines was also decreased by specific TRPV3 RNAi in carvacrol-treated 
sebocytes (Figure 2c).  
Taken together, our findings suggest that sebocytes might be involved in the pathogenesis 
of dry skin-associated inflammatory dermatoses linked to TRPV3 hyperactivity. Furthermore, 
our pre-clinical findings introduce TRPV3 as a previously unreported negative regulator of 
sebaceous lipid synthesis with a marked pro-inflammatory effect. Further clinical studies are 
urged to assess the clinical efficacy of TRPV3 inhibitors on the therapeutic management of 
certain inflammatory skin conditions. 
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Figure legends: 
Figure 1. Human sebocytes express functional TRPV3 ion channels 
a, Immunohistochemical staining of TRPV3 (3,3'-diaminobenzidine (DAB), brown precipitation) 
on human sebaceous glands (SG) and epidermis. NC, negative control. White and yellow 
arrowheads indicate undifferentiated and terminally differentiated cells, respectively. Scale bar = 
50 µm in each image. b, Immunocytochemical staining of TRPV3 (fluorescein isothiocyanate 
(FITC), green fluorescence) on SZ95 sebocytes. Blue: nuclei (4',6-diamidino-2-phenylindole 
(DAPI)). Scale bar = 25 µm. c, Western blot analysis of protein lysates of human epidermal 
keratinocytes (KC) and SZ95 sebocytes from pre- and postconfluent (pre and post, respectively) 
cultures followed by immunolabeling with anti-TRPV3 antibody. MW, molecular weight in kDa 
as indicated. Expected molecular weight of recombinant TRPV3 is ca. 91 kDa 
(http://www.uniprot.org/uniprot/Q2M3L1). Multiple bands may refer to uncharacterized post-
translational modifications, e.g. glycosylation, and multimerization of channel subunits. d, 
Relative expression of TRPV3 transcripts in pre- and postconfluent SZ95 sebocyte cultures. e, 
Representative Ca2+ signals on SZ95 sebocytes evoked by TRPV3 agonists 2-APB and carvacrol 
in the presence or absence of ruthenium red (RR) applied as indicated. f, Statistical analysis of 
the amplitudes of the Ca2+ signals in various conditions as indicated. N=6 in each group. 
***p<0.001 compared to the control and ###p<0.001 between the indicated groups as determined 
by ANOVA and Bonferroni post hoc test. g, Representative Ca2+ signals evoked by TRPV3 
agonists 2-APB (200 µM) and carvacrol (500 µM) on human SZ95 sebocytes transfected with 
scrambled RNA (scrRNA) or siRNA targeting TRPV3 (siRNA-TRPV3). h, Statistical analysis 
on the amplitude and the rate of rise of the 2-APB and carvacrol induced Ca2+ signals in 
sebocytes transfected with scrambled or siRNA targeting TRPV3, as indicated. N=5 in each 
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group. +p<0.05 and ++p<0.01 between the indicated groups as determined by two-tailed Student’s 
t-test for independent samples. 
 
Figure 2. Activation of TRPV3 inhibits lipid synthesis associated with sebaceous differentiation 
and induces the synthesis and release of pro-inflammatory cytokines 
a. Quantitative Nile Red staining of neutral lipids in scrambled RNA (scr RNA) and TRPV3 
targeting siRNA (siRNA-TRPV3) transfected SZ95 sebocytes treated with arachidonic acid and 
TRPV3 agonists for 24 hours, as indicated. N≥4 in each group. ***p<0.001 between the 
indicated groups as determined by One-way ANOVA and Bonferroni post hoc test. b. Relative 
expression of pro-inflammatory cytokine transcripts in SZ95 sebocytes after a 6-hour-long 
treatment with vehicle (used as control) or TRPV3 agonists, as indicated. #p<0.05 and ###p<0.001 
compared to the vehicle treated control using One-way ANOVA and Dunnett post hoc test. 
PPIA, Peptidylprolyl Isomerase A or cyclophyllin A used as endogenous control reference gene. 
c. Carvacrol (Carv, 500 µM, 6 hrs) induced changes in relative expression of pro-inflammatory 
cytokine genes (determined by Q-PCR). in scrambled RNA (scr RNA) and TRPV3 specific 
siRNA (siRNA-TRPV3) transfected SZ95 sebocytes. d. Release of pro-inflammatory cytokines 
(determined from supernatants using ELISA) following the same treatments as indicated in panel 
c.  +p<0.05, ++p<0.01 and +++p<0.001 between scrambled RNA and TRPV3 specific siRNA 
transfected and #p<0.05 between vehicle and carvacrol treated cells as determined by two-tailed 
Student’s t-test for independent samples. n.s., non-significant. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
SUPPLEMENTARY MATERIAL 
Supplementary materials and methods 
 
Materials 
Carvacrol, 2-Aminoethoxydiphenyl borate (2-APB), arachidonic acid (AA), testosterone, linoleic 
acid, and N-arachidonoylethanolamine (anandamide, AEA) were obtained from Sigma-Aldrich 
whereas AMG 9810 and HC067047 were from Tocris Bioscience (Bristol, UK). Ruthenium red 
was purcheased from Research Biochemicals International (Natick, MA, USA). 
Cell culturing 
Human immortalized SZ95 sebocytes, originated from human facial sebaceous glands (Zouboulis 
et al. 1999), were cultured in Sebomed® Basal Medium (Merck-Millipore, Berlin, Germany) 
supplemented with 10% fetal bovine serum (Life Technologies Corporation, Carlsbad, CA, USA), 
1 mM CaCl2, 5 ng/ml human recombinant epidermal growth factor (Sigma-Aldrich), 50 IU/ml 
penicillin and 50 μg/ml streptomycin (both from PPA Laboratories, Pasching, Austria). The 
medium was changed every other day, and cells were sub-cultured at 60-70% confluence. Human 
keratinocytes were isolated from skin samples of healthy individuals undergoing dermatosurgery 
following written informed consent adhering to Helsinki guidelines, and after obtaining 
Institutional Research Ethics Committee’s and Government Office for Hajdú-Bihar County’s 
permission (protocol No.: DE OEC RKEB/IKEB 3721-2012). Primary keratinocytes were handled 
and cultured as described previously (Szöllősi et al. 2018). 
Immunocytochemistry 
SZ95 sebocytes, seeded and cultured on sterile coverslips in 24-well plates, were fixed in ice-cold 
acetone (VWR, Radnor, PA, USA) for 5 min and then permeabilized by 0.1% Triton-X-100 in 
phosphate-buffered saline (PBS; 115 mM NaCl, 20 mM Na2PO4, pH 7.4; all from Sigma-Aldrich) 
for 10 min. After washing in PBS and blocking in 1% bovine serum albumin (BSA, Sigma-
Aldrich) in PBS for 30 min, cells were incubated with the TRPV3 (AbCam, Cambridge, UK) 
specific primary antibodies (produced in rabbit; dilution 1:200 in blocking solution; overnight 
incubation at 4°C). For fluorescence staining, slides were then incubated with fluorescein 
isothiocyanate (FITC)-conjugated goat IgG-specific secondary antibody (Life Technologies) for 
60 min (dilution 1:200), and the nuclei of cells were visualized using 4',6-diamidino-2-
phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA). Cells were examined on a 
Nikon Eclipse E600 fluorescent microscope (Nikon, Tokyo, Japan). As negative control, the 
primary antibody was omitted from the procedure. 
 
  
Immunohistochemistry 
The immunohistochemical investigation of TRPV3 was performed on formalin fixed paraffin 
embedded, skin samples rich in sebaceous glands, all diagnosed as trichilemmal cyst in Kenézy 
County Hospital (Debrecen, Hungary). Serial 4 μm thick sections were cut from paraffin blocks. 
Heat-induced antigen retrieval was performed on formalin fixed samples. EDTA buffer (Reanal, 
Hungary, 1 mM, pH 8.0) was applied in microwave oven for 15 min to unmask epitope of TRPV3. 
Endogenous peroxidase activity was blocked with 3% H2O2 (Sigma-Aldrich) for 10 minutes. After 
blocking, tissue sections were incubated with a specific rabbit primary antibody against TRPV3 
(Alomone, Jerusalem, Israel, 1:500, 60 min). TRPV3 expression was detected with HRP labelled 
Polymer Anti Rabbit EnVision+ system (Dako, Glostrup, Denmark) following the manufacturers 
protocol TRPV3 staining was visualized with 3,3'-Diaminobenzidine (DAB, DAKO, Golstrup, 
Denmark), nuclei were counterstained with hematoxylin (Sigma-Aldrich) and tissue sections were 
finally mounted in permanent mounting medium (Histolab, Göteborg, Sweden). Negative controls 
were obtained by omitting the primary antibody. 
 
Determination of intracellular lipids 
For quantitative measurement of lipid content, cells (20,000 cells/well) were cultured in 96-well 
black-well/clear-bottom plates (Greiner Bio-One, Frickenhausen, Germany) in quadruplicates and 
were treated with compounds for 24 hours. Subsequently, supernatants were discarded and 100 µl 
of a 1 µg/ml Nile Red (Sigma-Aldrich) solution in PBS was added to every well. Fluorescence 
was measured on a FlexStation 3 multi-mode microplate reader (Molecular Devices, San 
Francisco, CA). Results are expressed as percentages of the relative fluorescence units in 
comparison with the controls using 485 nm excitation and 565 nm emission wavelengths for 
neutral lipids (Alestas et al. 2006; Dobrosi et al. 2008). 
 
Determination of viability 
Viability was determined by measuring the conversion of the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich) to formazan by mitochondrial 
dehydrogenases. Cells were plated in 96-well plates (in 20,000 cells/well density) in 
quadruplicates and were treated with compounds for 24-hours. Cells were then incubated with 0.5 
mg/ml MTT for 3 hours, subsequently colorimetric analysis of the concentration of formazan 
crystals took place according to the manufacturer’s instruction. 
 
Fluorescent Ca2+-measurement 
SZ95 sebocytes were seeded in 96-well black-well/clear-bottom plates (Greiner Bio-One) at a 
density of 20,000 cells/well. Cells were washed once with 1% BSA and 2.5 mM probenecid (both 
from Sigma-Aldrich) containing Hank’s solution (136.8 mM NaCl, 5.4 mM KCl, 0.34 mM 
Na2HPO4, 0.44 mM KH2PO4, 0.81 mM MgSO4, 1.26 mM CaCl2, 5.56 mM glucose, 4.17 mM 
NaHCO3, pH 7.2, all from Sigma-Aldrich), and loaded with 1 μM Fluo-4 AM (Life Technologies) 
dissolved in Hank’s solution (100 μl/well) at 37°C for 30 min, and were then washed three times 
with Hank’s solution (100 μl/well). The plates were then placed in a FlexStation 3 multi-mode 
microplate reader (Molecular Devices), and changes in cytoplasmic Ca2+ concentration (reflected 
by changes in fluorescence at 490 nm excitation and 520 nm emission wavelengths) induced by 
various TRPV3 agonist in various conditions were monitored. Experiments were performed in 
multiple wells and data were obtained as F/F0, where F0 is the average fluorescence of the baseline 
(before compound application) and F is the actual fluorescence.  
 
RNA isolation, reverse transcription, quantitative “real-time” PCR (Q-PCR) 
Total RNA was isolated using TRIzol reagent (Life Technologies) according to the manufacturer’s 
protocol, and the isolated RNA was quality-checked by Nanodrop-1000 Spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA). 2 μg of total RNA were then reverse-transcribed into 
cDNA by using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) according 
to the manufacturer’s protocol. PCR amplification was performed by using the TaqMan primers 
and probes (assay ID-s: Hs00376854_m1 for TRPV3, Hs00985639_m1 for IL-6, Hs00174103_m1 
for IL-8, Hs00174092_m1 for IL-1α, Hs00174128_m1 for TNFα, Hs00234592_m1 for PPARγ 
and Hs00942766_s1 for NRIP1) using the TaqMan universal PCR master mix protocol (Life 
Technologies). As internal controls, transcripts of peptidyl-prolyl isomerase A (Cylophylin A, 
PPIA) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined (assay ID-s: 
Hs99999904_m1 for PPIA and Hs99999905_m1 for GAPDH). The amount of the transcripts was 
normalized to those of the housekeeping gene using the ΔCT method. 
 
Western blotting 
Cells were harvested and homogenized in detergent mixture (50 mM TRIS HCl, 150 mM NaCl, 
1% Triton X-100, 1% Igepal CA 630, 0.5% sodium deoxicholate), containing protease inhibitor 
cocktail (1:100, all from Sigma-Aldrich). After ultrasonic homogenization, the protein content of 
the resulting samples was determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). 
Protein samples (30 µg/well) were subjected to SDS-PAGE (10% Mini Protean TGX gels, Bio-
Rad, Hercules, CA, USA), and transferred to nitrocellulose membranes, by using Trans-Blot® 
Turbo™ Nitrocellulose Transfer Packs and Trans Blot Turbo System (both from Bio-Rad). 
Membranes were probed with the rabbit primary antibody against human TRPV3 (1: 200 dilution, 
Alomone Labs, Jerusalem, Israel), in PBS containing 1% dry milk and 0.1% Tween-20) overnight 
at 4°C. As a secondary antibody, horseradish peroxidase-conjugated anti-rabbit IgG antibody 
(1:1000, Sigma) was used and the immunoreactive bands were visualized by a SuperSignal West 
Pico or Femto Chemiluminescent Substrate-Enhanced Chemiluminescence kits (Pierce) using a 
Kodak Gel Logic 1500 Imaging System (Kodak, Tokyo, Japan). To assess equal loading, the 
membranes were re-probed by using rabbit-anti-tubulin antibody (1:1000, AbCam).  
 
RNA interference 
Cells were transfected at ≈70% confluence with specific Stealth RNAi oligonucleotides (40 nM, 
Invitrogen) against TRPV3 (ID: HSS175965), using Lipofectamine RNAiMax Transfection 
Reagent (Invitrogen). For controls, Stealth RNAi Negative Control Med GC Duplexes (scrambled 
RNA construct; Invitrogen) were employed. The efficacy of RNAi-driven ‘‘knock-down’’ was 
evaluated 48 hours after transfection by Western blotting and Q-PCR as described previously 
above.  
 
Determination of cytokine release (ELISA) 
Supernatants were collected from sebocytes exposed to various treatments. While RNA was 
isolated from the cells as described above, the supernatants were analyzed for human IL-1α, IL-
1β, IL-6, IL-8/CXCL-8 and TNFα using commercially available ELISA kits (BD Biosciences, 
Franklin Lakes, NJ, USA) according to the manufacturer’s protocols. In brief, plates were coated 
with capture antibody diluted in coating buffer (0.1 M Na2CO3, pH 9.5 with 10 N NaOH) and 
incubated overnight at 4°C. Then plates were incubated with assay diluent (10% fetal bovine serum 
in PBS) at room temperature (RT) for 1 hour, while standard and sample dilutions were prepared 
in assay diluent. Concentration standards and samples were added into appropriate wells and 
incubated for 2 hrs at RT. After 2 hours, working detector (detection antibody + SAv-HRP reagent) 
was added to each well, and incubated for 1 hour at RT. After every step, plates were washed with 
wash buffer (0.05% Tween-20 in PBS). After washing, substrate solution (tetramethylbenzidine 
and hydrogen peroxide in citrate-buffer, pH 5.0) was added to every well for 30 minutes in the 
dark, followed by stop solution (2 N H2SO4). Absorbance was read at 405 nm within 30 minutes 
of stopping reaction. The amount of cytokines in pg/ml was calculated from calibration curve 
created by serial dilution of interleukine standards. The experiments were repeated 3 times using 
supernatants of independent cultures. TNFα was not detected in the supernatants (data not shown). 
 
Determination of cellular differentiation by flow cytometry 
SZ95 cells were cutured in 6-well plates and exposed to various treatments for 24 hrs. Then, cells 
were stained with Nile Red (1 µg/ml Nile Red solution in PBS) for 30 minutes. Following staining, 
cells were harvested and subjected to flow cytometry in a NovoCyte Flow Cytometer (ACEA 
Biosciences, San Diego, CA, USA) using a 488 nm extinction laser. Side scatter and fluorescence 
characteristic for Nile Red via FL-2 channel were detected simultaneously and data were analyzed 
using FlowJo (FlowJo LLC, Ashland, OR, USA) software. 
 
Data and statistical analysis 
Unless it is stated otherwise, all data are presented as mean±SEM of the indicated sample size 
where n represents the number of independent biological repeats. Data analysis and plotting were 
carried out using Origin 9.0 (OriginLab Corporation, Northampton, MA, USA). Comparison of 
means was done by two-tailed Student’s t-test or, in case of multiple groups, by One-Way ANOVA 
followed by either Dunnett or Bonferroni post hoc tests, as appropriate. All statistical analyses 
were performed using IBM SPSS Statistics 23.0 (IBM, Armonk, NY, USA). 
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Supplementary Figure S1. RNAi-mediated silencing of TRPV3 expression in human sebocytes 
SZ95 sebocytes were transfected with either scrambled RNA (scr RNA) or siRNA targeting 
TRPV3 (siRNA-TRPV3) as detailed in the ‘Supplementary materials and methods’ section. 
Expression of TRPV3 was checked 48 hours after transfection. a, Western blot analysis of 
sebocytes transfected with scrambled RNA (lane 1) or siRNA specifically targeting TRPV3 (lane 
2) indicates a marked decrease of TRPV3 protein expression at 48 hours after transfection Tubulin 
stained on the same membrane served as a loading control to asses equal amount of total protein 
loaded to the PAGE. OD: relative optical density of the TRPV3 bands normalized to the 
corresponding tubulin bands. OD of scrambled RNA transfected sebocytes = 1. b, Quantitative 
analysis of TRPV3 transcripts by Q-PCR in scrambled RNA (scr RNA) and TRPV3-specific 
siRNA (siRNA-TRPV3) transfected sebocytes reveals a significant decrease of TRPV3 gene 
expression at 48 hour after transfection. N=3 independently transfected samples, **p<0.01 
between the scr RNA and siRNA-TRPV3 transfected samples as determined by Student’s t-test 
for independent samples. In other experiments, pharmacological treatments of scr RNA and 
siRNA-TRPV3-transfected cells were started 48 hours after transfection. 
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Supplementary Figure S2. Concentration dependent effect of TRPV3 agonists on cytoplasmic 
Ca2+ concentration and viability of SZ95 sebocytes 
a. Statistics on the amplitude of cytoplasmic Ca2+ signals evoked by acute application of TRPV3 
agonists in the indicated concentrations. N=3 in each group. b. Effect of the TRPV3 agonists on 
the viability of SZ95 cells as measured by MTT assay. N=7-8 in each group, ***p<0.001 compared 
to the vehicle treated control group as determined by One-way ANOVA and Dunnett post hoc test. 
TRPV3 agonists were applied in the same concentrations as on panel a for 24 hours prior the assay. 
Although high concentrations significantly reduced the MTT signal indicating declined living cell 
number, lower concentrations of the agonists did not decreased cellular viability after 24 hours. In 
other experiments, these effective but non-toxic concentrations (150 µM 2-APB and 500 µM 
carvacrol) were tested on lipid synthesis and cellular differentiation (24 hr-treatments) and 
inflammatory cytokine expression and release (6 hr-treatments).  
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Supplementary Figure S3. Effect of TRPV3 agonists on lipid synthesis of human sebocytes 
2-APB and Carvacrol were tested on the basal and induced lipogenesis of SZ95 cells. Lipogenesis 
was induced either by the combination of 100 µM linoleic acid and 1 µM testosterone (LA+T) 
(Makrantonaki and Zouboulis 2007) or by the endocannabinoid anandamide 
(arachidonoylethanolamine, AEA, 30 µM) (Dobrosi et al. 2008). The presence of TRPV3 agonists 
significantly decreased both basal and induced lipid synthesis. N≥4 in each group, ***p<0.001 
compared to the control and ###p<0.001 between the indicated groups as determined by One-way 
ANOVA and Bonferroni post hoc test. 
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Supplementary Figure S4. Effect of TRPV3 agonist carvacrol on cellular differentiation of 
human sebocytes 
a. SZ95 sebocytes were treated with vehicle, arachidonic acid (AA, 100 µM), carvacrol (500 µM), 
ruthenium red (RR, 10 µM) and combinations of the compounds as indicated in the figure for 48 
hrs. Cells were stained with Nile red solution then harvested and subjected for flow cytometry as 
described in the Supplementary materials and methods. Fluorescence of Nile red staining and side 
scatter (SSC) were detected in parallel to assess cellular lipid content and granularity, respectively. 
AA induced a marked differentiation of the cells indicated by increased lipid accumulation and 
granulation of SZ95 cells. Carvacrol increased cellular lipid content only moderately, however it 
inhibited the AA induced cellular lipid accumulation. These effects of carvacrol were abolished 
by the TRPV3 blocker RR suggesting that activation of TRPV3 inhibits AA induced lipid 
accumulation. In contrast, neither basal nor AA-induced granulation of sebocytes were influenced 
by carvacrol, suggesting that TRPV3 activation primarily affects lipid synthesis, and it has no 
effect on other processes of differentiation. b. Relative expression of peroxisome proliferator-
activated receptor γ (PPARγ) and nuclear receptor interacting protein 1 (NRIP1) positively 
regulating sebaceous lipid synthesis during sebocytes’ differentiation was determined by QPCR 
after treating cells with 500 µM carvacrol or vehicle for 24 hrs. Carvacrol markedly downregulated 
the expression of genes regulating lipid synthesis. N=3 independent determinations. 
 
